Authors
Latest:
Dr. Karmali on Optimizing Maintenance Therapy in Older Patients With MCLReem Karmali, MD, MS, discusses next steps for optimizing maintenance therapy in older patients with mantle cell lymphoma.
Latest:
Dr. Luke on Future Research With T-Cell Therapy in MelanomaJason J. Luke, MD, FACP, discusses the future of T-cell therapy in melanoma.
Latest:
Trial of Triplet Regimen With Cabozantinib Plus Immunotherapy Is Planned in RCCInvestigators see potential in adding targeted therapy to dual immunotherapy for intermediate- and poor-risk patients with renal cell carcinoma. In the phase III COSMIC-313 trial, investigators aim to evaluate cabozantinib, nivolumab, and ipilimumab in patients with untreated advanced RCC.
Latest:
CLL1-Targeted CAR T-Cell Therapy Shows Early Promise in Pediatric AMLResults of a phase 1/2 trial show the feasibility of an approach targeting CLL1 in pediatric patients with relapsed or refractory acute myeloid leukemia.
Latest:
Dr. Bauml on KEYNOTE-055 Study for Patients With HNSCCJoshua M. Bauml, MD, assistant professor of Medicine, Hospital of the University of Pennsylvania and the Veteran's Administration Medical Center, discusses the preliminary results of the KEYNOTE-055 study, which investigated pembrolizumab (Keytruda) after failure on platinum-based therapy and cetuximab in patients with head and neck squamous cell carcinoma.
Latest:
Dr. McDermott on the Promise of Pembrolizumab in Non-Clear Cell RCCDavid F. McDermott, MD, director of the Biologic Therapy Program at Beth Israel Deaconess Medical Center, discusses the promise of single-agent pembrolizumab in advanced non–clear cell renal cell carcinoma.
Latest:
Dr. Lee on Nanotechnology Combination Therapy in RCCBenjamin R. Lee, MD, chief, Division of Urology, University of Arizona College of Medicine-Tucson Department of Surgery, and director of the Genitourinary Cancer and Disease Oriented Strategic Planning Team, University of Arizona Cancer Center, discusses nanotechnology combination therapy for patients with renal cell carcinoma (RCC).
Latest:
Dr. Mary Jo Fidler on the Role of Oligoclonal T Cell Expansion in NSCLCMary Jo Fidler, MD, associate professor, medical oncology, hematology, internal medicine, Rush University Medical Center, discusses how early and persistent oligoclonal T cell expansion correlates with durable response to anti-PD1 therapy in non-small cell lung cancer treatment (NSCLC).
Latest:
Dr. Uzzo on Potential of Adjuvant Therapy in Patients With RCCRobert G. Uzzo, MD, chair, Surgical Oncology, G. Willing "Wing" Pepper Chair in Cancer Research, senior vice-president, Physician Services, president, Fox Chase Cancer Center Medical Group, Inc., professor of Surgery, Temple University Health System, Fox Chase Cancer Center, discusses recent outcomes of adjuvant therapy as seen in clinical trials for patients with renal cell carcinoma (RCC).
Latest:
Dr. Figlin on TKI Therapy Options in Renal Cell CarcinomaRobert A. Figlin, MD, the Steven Spielberg Family Chair in Hematology-Oncology and associate director of academic program development in the Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center, discusses tyrosine kinase inhibitors that he uses to treat patients with renal cell carcinoma.
Latest:
Dr. Siegel Discusses RT-Related AEs for Patients With Oropharyngeal Squamous Cell CarcinomasRobert Siegel, MD, chair, professor of medicine, director, Division of Hematology/Oncology, George Washington University, discusses the adverse events (AEs) associated with radiation therapy (RT) for patients with oropharyngeal squamous cell carcinomas.
Latest:
Dr. Bosse on the Safety Profile With Radium-223 Plus VEGF in RCCDominick Bosse, MD, fellow, Dana-Farber Cancer Institute, discusses the safety profile demonstrated with the combination of radium-223 and VEGF-targeted therapy for patients with renal cell carcinoma (RCC).
Latest:
Dr. Ai on the FDA Approval of Mogamulizumab in CTCLWei Z. Ai, MD, hematologist, University of California, San Francisco, discusses the FDA approval of mogamulizumab for the treatment of patients with cutaneous T-cell lymphoma who have received at least 1 prior systemic therapy.
Latest:
Dr. Flinn on FDA Approval of Tisagenlecleucel in DLBCLIan W. Flinn, MD, PhD, director of Lymphoma Research, principal investigator, Sarah Cannon Research Institute, discusses the FDA approval of the chimeric antigen receptor T-cell therapy tisagenlecleucel (Kymriah) for use in adult patients with relapsed/refractory large B-cell lymphoma—including diffuse large B-cell lymphoma.
Latest:
Dr. Gieschen on the Side Effects of Radiation Therapy in NSCLCHolger L. Gieschen, MD, assistant professor, Department of Radiology, the University of Tennessee Health Science Center, radiation oncologist, West Cancer Center, discusses the safety profile of radiation therapy in patients with non–small cell lung cancers (NSCLC).
Latest:
Dr. Nanus Discusses Adjuvant Therapy for RCCDavid M. Nanus, MD, medical oncologist, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses adjuvant therapy for patients with renal cell carcinoma.
Latest:
Dr. Goldberg on Sequencing Following Treatment With Osimertinib in NSCLCSarah B. Goldberg, MD, MPH, an assistant professor of medicine at the Yale School of Medicine and Yale Cancer Center, discusses sequencing after therapy with osimertinib (Tagrisso) in EGFR-positive non–small cell lung cancer.
Latest:
Dr. Larner on Integrating Radiation Therapy With Immune Checkpoint Blockade in NSCLCJames Larner, MD, professor and chair of Radiation Oncology, University of Virginia Health System, discusses integrating radiation therapy with immune checkpoint blockade in patients with non–small cell lung cancer (NSCLC).
Latest:
Dr. Pacheco on Frontline Therapy for Patients With EGFR-Mutant NSCLCJose M. Pacheco, MD, an assistant professor of medicine/medical oncology at the Colorado University School of Medicine, discusses frontline therapy for patients with EGFR-mutant non–small cell lung cancer (NSCLC).
Latest:
Dr. Van Veldhuizen Discusses Combination Therapy in RCCPeter J. Van Veldhuizen, MD, hematologist/oncologist, Sarah Cannon Research Institute, discusses combination therapy for the treatment of patients with renal cell carcinoma.
Latest:
Dr. Agarwal on Second-Line Therapy Selection in Metastatic RCCNeeraj Agarwal, MD, associate professor, Division of Oncology, Department of Medicine, University of Utah School of Medicine, Huntsman Cancer Institute, discusses second-line therapy selection in metastatic renal cell carcinoma.
Latest:
More Data Are Needed For EGFR-Targeted Agents in NSCLCEdward B. Garon, MD, discusses the landscape of EGFR-targeted therapy in non–small cell lung cancer.
Latest:
Dr. Patel on Induction in Patients With Mantle Cell LymphomaKrish Patel, MD, medical oncologist, Swedish Cancer Institute, discusses induction therapy in patients with mantle cell lymphoma (MCL).
Latest:
Dr. Mix on Local Consolidative Therapy in Oligometastatic NSCLCMichael D. Mix, MD, assistant professor of radiation oncology at Upstate University Hospital, discusses the use of local consolidative therapy in patients with oligometastatic non–small cell lung cancer (NSCLC).
